> 资讯    /    正文

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will participate in the following upcoming investor conferences:

  • Needham 24th Annual Virtual Healthcare Conference: Zymeworks’ management will participate in virtual one-on-one meetings and present on April 8 at 9:30 am Eastern Time (ET).
  • Stifel 2025 Virtual Targeted Oncology Forum: Zymeworks’ management will participate in virtual one-on-one meetings and a fireside chat on April 9 at 12:30 pm ET.

About Zymeworks Inc.

Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat conditions such as cancer, inflammation, and autoimmune disease. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz Pharmaceuticals), granting each exclusive rights to develop and commercialize zanidatamab in different territories. The U.S. FDA granted accelerated approval of Ziihera® (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive (IHC 3+) second-line biliary tract cancer (BTC). Ziihera® is the first and only dual HER2-targeted bispecific antibody approved for HER2-positive BTC in the U.S. Zanidatamab is currently under regulatory review in the EU and China for second-line BTC and is being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with multiple HER2-expressing cancers. Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are now actively recruiting with an investigational new drug application for ZW251 planned for mid-2025. In addition to Zymeworks’ pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.

Contacts:

Investor Inquiries:
Shrinal Inamdar
Senior Director, Investor Relations
(604) 678-1388 
ir@zymeworks.com   

Media Inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388 
media@zymeworks.com

最新文章

Zymeworks Announces Participation in Upcoming Investor Conferences Copenhagen Infrastructure Partners enters partnership with GC Storage Services for 2.3GW pipeline of 北京管道“京才”计划:人才驱动新质生产力跃升 国药控股公布2024年度业绩 业务模式快速转型升级 三大主营业务差异化发展 红色教育修党性  支部共建聚合力——农发行津市市支行党支部联合农发行澧县支行党支部开展党建共建活动 农发行湘潭市分行:精准施策 施足春耕备耕“金融底肥”

Copyright © 2024 商圈 All Rights Reserved.

本站部分内容来源于用户投稿,内容相关Q:230098551